Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05591118 · ClinicalTrials.gov registry record · Phase 3
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
A Phase 3 study of Pulmonary Embolism, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT05591118 is a Phase 3 study of Pulmonary Embolism that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 500 participants, below the 3,048-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT05591118, a Phase 3 study of Pulmonary Embolism, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilation.
Conditions Studied
Interventions
- DRUG Anticoagulant Therapy
- DEVICE Catheter-Directed Therapy
Study Locations (20)
California
- Stanford Medicine - Palo Alto
- UC Davis Health - Sacramento
- Scripps Memorial Hospital, La Jolla - San Diego
- The Lundquist Institute - Torrance
Illinois
- University of Chicago Medical Center - Chicago
- Advocate Good Samaritan Hospital - Downers Grove
- Loyola University Chicago - Maywood
- Southern Illinois University School of Medicine - Springfield
Florida
- Baptist Health Miami Cardiac & Vascular Institute - Miami
- University of South Florida/ Tampa General Hospital - Tampa
Massachusetts
- Boston Medical Center - Boston
- Beth Israel Deaconess Medical Center - Boston
Michigan
- University of Michigan - Ann Arbor
- Trinity Health - Ann Arbor Hospital - Ypsilanti
Alabama
- The University of Alabama At Birmingham - Birmingham
Delaware
- Christiana Care - Newark
District of Columbia
- MedStar Health Research Institute - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-07-17 |
| Est. Completion | 2027-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05591118
The ClinicalTrials.gov registry entry for NCT05591118 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,048-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (84% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Embolism appearing as the primary indexed condition, and to 2 interventions - of which Anticoagulant Therapy is the first listed.
NCT05591118 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT05591118 about?
NCT05591118 is a clinical study titled "Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy". PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilation.
What is the current status of trial NCT05591118?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2023-07-17. Estimated completion is 2027-06-26.
What conditions does trial NCT05591118 study?
This clinical trial studies the following conditions: Pulmonary Embolism.
What interventions are being tested in trial NCT05591118?
The interventions under investigation include: Anticoagulant Therapy (DRUG), Catheter-Directed Therapy (DEVICE).
Who is sponsoring clinical trial NCT05591118?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05591118 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Embolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
ACTIVE NOT RECRUITING · Phase 3
-
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
COMPLETED · Phase 3
-
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
COMPLETED · Phase 3
-
A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.